Cas9 Stable Cell Line - LoVo

The LoVo cell line was originally established in 1971 from a metastatic tumor nodule resected from the left supraclavicular region of a 56-year-old male patient diagnosed with grade IV Dukes C colorectal adenocarcinoma. Derived from the large intestine, these epithelial cells grow adherently and are known for producing carcinoembryonic antigen (CEA). The line exhibits a hyperdiploid karyotype with stable yet homogeneous chromosomal features and expresses several oncogenes, including c-myc, K-ras, H-ras, and N-ras. It is tumorigenic in nude mice. The Cas9 Stable Cell Line - LoVo is derived from this parental line through stable integration and constitutive expression of the CRISPR-associated protein 9 (Cas9) nuclease. This engineered variant eliminates the need for transient Cas9 delivery via plasmid transfection or ribonucleoprotein complexes, providing a consistent and reproducible platform for genome editing experiments. The constitutively expressed Cas9 can be readily directed by synthetic guide RNAs to induce double-strand breaks at target genomic loci.

The Cas9 Stable Cell Line - LoVo is particularly suited for loss-of-function studies in colorectal cancer research. Researchers can use it to perform high-throughput genetic screens, investigate drug resistance mechanisms, and study tumor suppressor gene function in a physiologically relevant colon adenocarcinoma background. The stable Cas9 expression streamlines experimental workflows, reducing batch-to-batch variability and allowing for more consistent editing efficiencies across multiple rounds of transfection. This cell line also supports the generation of isogenic knockout clones for downstream functional validation, including proliferation assays, apoptosis studies, and migration or invasion analyses. Additionally, it can be used in combination with synthetic guide RNA libraries for pooled CRISPR screens aimed at identifying novel therapeutic targets or genes involved in metastatic progression. The LoVo background, with its well-characterized mutational profile and CEA production, makes this Cas9-stable line a valuable tool for both basic cancer biology research and preclinical drug development efforts targeting colorectal cancer pathways.